MTARC1 and metabolic dysfunction-associated steatotic liver disease: HSD17B13 rs72613567 and MTARC1 rs2642438 variant carriers, which have been associated with lower rates of NAFLD, benefitted less from statins as noncarriers.28,42 Nevertheless, it would be desirable to perform the analyses in larger cohorts, especially for homozygous minor allele carriers, to exclude that the lack of significance is attributable to small group sizes.